Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Sofinnova Partners
BioCentury | Mar 25, 2025
Finance
Sofinnova’s ‘pan-European’ play, China innovation and Trump’s tariff threat — a BioCentury podcast
How Biovelocita became the largest life sciences accelerator in Europe, the latest at FDA and more
BioCentury | Mar 18, 2025
Finance
Strategics back Sofinnova Partners’ ‘pan-European’ accelerator in €165M fund
Following eight-year ‘pilot experiment’ in Italy, the firm’s Biovelocita now builds companies across Europe
BioCentury | Mar 7, 2025
Finance
Strategics back Trimtech’s protein cluster degraders with $31M: Finance Report
Pharma venture arms join founding investors CIC, DDF to back U.K. start-up; plus venture rounds for Garuda, Ataraxis and Callio, and Tenaya’s follow-on
BioCentury | Mar 4, 2025
Finance
Sofinnova set to back dozens of biotechs with €1.2B across strategies
European firm to invest fresh cash across all company stages amid changes in LP base, portfolio composition
BioCentury | Feb 13, 2025
Finance
Newleos launches with $93.5M, neuropsychiatry candidates from Roche: Venture Report
Plus: DeepMind veterans raise $50M for AI-guided protein design start-up; crossovers back Abcuro’s pivotal study; and more
BioCentury | Dec 13, 2024
Finance
Techbio VC Dimension upsizes for $500M second fund; PE firm takes stake in Andera
In BioCentury’s Venture Report: Fundings for Citryll, Angitia, Tasca, Veradermics and more
BioCentury | Dec 12, 2024
Deals
Nvelop, Chroma merger creates opportunity for targeted epigenome editors
Nvelop CEO Jeff Walsh will lead nChroma, which has $75M in new funding and a lead for HBV
BioCentury | Dec 6, 2024
Emerging Company Profile
Disco: Mapping protein communities on cancer cell surfaces
German biotech has already mapped small cell lung cancer surface proteins, colorectal is next
BioCentury | Nov 23, 2024
Finance
Latest Jeito bet positions European VC for fourth exit
Mega-round for Alentis spotlights French firm’s investment style
BioCentury | Oct 25, 2024
Finance
Why Rice is launching a venture studio in Houston’s emerging biotech ecosystem
Founders see chance to build start-ups from university IP, with clinical infrastructure already in place from local institutions
Items per page:
1 - 10 of 472